Creative Medical Technology Holdings, INC 10-Q quarterly reports

Creative Medical Technology Holdings, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in R&D, strategic financing through warrant exercises, and progress in its regenerative medicine pipeline.

Creative Medical Technology Holdings reports a net loss of $1.4 million for Q1 2026 as it continues to advance its regenerative medicine clinical pipeline.

Creative Medical Technology Holdings, Inc. reported an increased net loss for the nine months ended September 30, 2025, despite significant clinical trial advancements and successful capital raises through warrant exercises.

Creative Medical Technology Holdings, Inc. reported an increased net loss for Q2 2025 despite significant clinical trial advancements and a successful warrant exercise raising $3.7 million.

Creative Medical Technology Holdings reports its financial results for the first quarter of 2025, highlighting revenue generation, increased R&D spending, and proceeds from warrant exercises.

Creative Medical Technology Holdings reports a net loss of $1.04 million for the third quarter of 2024, while progressing its clinical trials and research programs.

Creative Medical Technology Holdings reports a net loss of $1.56 million for the second quarter of 2024, with a slight increase in revenue and a significant rise in research and development expenses.

Creative Medical Technology Holdings reports a net loss of $1.04 million for the first quarter of 2024, while making progress in its clinical programs and securing Orphan Drug Designation.